G
G

GSK

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Haleon not a party to U.S. litigation focused on Zantac - spokesperson

By Natalie Grover LONDON, Aug 11 (Reuters) - Haleon - GSK's recently spun off consumer health unit - is not a party to U.S. litigation focused on the heartburn medicine Zantac, a spokesperson told Reuters on Thursday. "We have never marketed Zantac in any form in the U.S., as Haleon or as GSK consumer healthcare," the spokesperson said, responding to Reuters querying a near-20% decline in Haleon's share price this week.
G
P
S

Haleon not a party to U.S. litigation focused on Zantac - spokesperson

LONDON, Aug 11 (Reuters) - Haleon - GSK's recently spun off consumer health unit - is not a party to the U.S. litigation focused on the heartburn medicine Zantac, a spokesperson told Reuters on Thursday. "We have never marketed Zantac in any form in the U.S., as Haleon or as GSK consumer healthcare," the spokesperson said in response to queries about sharp declines in Haleon shares.
G
S

FTSE 100 ends down as GSK slumps, eyes on GDP data

(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window) * Rio Tinto down on ex-dividend trading * GSK, Haleon slide on U.S. litigation concerns * Network International jumps on share buyback, earnings * FTSE 100 down 0.6%, FTSE 250 off 0.3% (Updates with market close) By Sruthi Shankar Aug 11 (Reuters) - Britain's main stock indexes closed lower on Thursday, with the blue-chip FTSE 100 hit by a slump in healthcare stocks and the midcap index slippin
A
A
G
N
R
U

FTSE 100 stalls as Rio Tinto, healthcare stocks weigh

(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window) * FTSE 100 flat, FTSE 250 adds 0.4% Aug 11 (Reuters) - Britain's top share index was flat on Thursday, weighed down by Rio Tinto and healthcare stocks, while the midcap index hit a fresh two-month high as global equities extended gains on relief from softer-than-expected U.S.
G
U

UK Stocks-Factors to watch on July 29

July 29(Reuters) - Britain's FTSE 100 index .FTSE is seen opening higher on Friday, with futures FFIc1 up 0.35%. * ASTRAZENECA: AstraZeneca AZN.L topped analyst expectations for second-quarter profit and revenue, helped by higher demand for its cancer medicines. * IAG: IAG IAG.L returned to quarterly profitability for the first time since the outbreak of the COVID-19 pandemic, following a "significant" increase in capacity.
A
C
E
G
G
I
I
J
R
S
U

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.